Disclosed herein are compounds that activate RNaseL, methods of synthesizing compounds that activate RNaseL and the use of compounds that activate RNaseL for treating and/or ameliorating a disease or a condition, such as a viral infection, a bacterial infection, cancer and/or parasitic disease.
[EN] 2-5A ANALOGS AND THEIR METHODS OF USE<br/>[FR] ANALOGUES DE 2-5A ET LEURS PROCÉDÉS D'UTILISATION
申请人:ALIOS BIOPHARMA INC
公开号:WO2011005595A2
公开(公告)日:2011-01-13
Disclosed herein are compounds that activate RNaseL, methods of synthesizing compounds that activate RNaseL and the use of compounds that activate RNaseL for treating and/or ameliorating a disease or a condition, such as a viral infection, a bacterial infection, cancer and/or parasitic disease.
Synthesis and Enzymatic Deprotection of Fully Protected 2′-5′ Oligoadenylates (2-5A): Towards a Prodrug Strategy for Short 2-5A
Fullyprotected pA2′p5′A2′p5′A trimers 1a and 1b have been prepared as prodrug candidates for a short2′‐5′ oligoadenylate, 2‐5A, and its 3′‐O‐Me analog, respectively. The kinetics of hog liver carboxyesterase (HLE)‐triggered deprotection in HEPES buffer (pH 7.5) at 37° has been studied. The deprotection of 1a turned out to be very slow, and 2‐5A never appeared in a fully deprotected form. By contrast